Preliminary evaluation of prostate cancer metastatic risk biomarkers.
Prostate cancer patients at high risk of metastasis need to be identified as early as possible since metastasis is invariably fatal. Treatment could be tailored to risk. Recent array comparative genomic hybridization (aCGH) studies of primary and metastatic prostate tumors identified 39 BAC clones capable of detecting genomic signatures of metastasis. We termed these loci the genomic evaluators of metastatic CaP (GEMCaP). Risk assessments were made on a set of men who were managed with radical prostatectomy. We compared the utility of GEMCaP loci and the Kattan nomogram, a common risk assessment tool, in relation to biochemical outcome. This preliminary evaluation experiment suggests we can use aCGH to detect genomic signatures of metastasis in primary tumors with an accuracy of 78%. The classification accuracy for the Kattan nomogram was 75%. Therefore, validation of GEMCaP is warranted in a larger, appropriately designed cohort.
Paris
P L
PL
Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA.
Weinberg
V
V
Simko
J
J
Andaya
A
A
Albo
G
G
Rubin
M A
MA
Carroll
P R
PR
Collins
C
C
D014408:Biomarkers, Tumor / Q000032:analysis*; D003131:Combined Modality Therapy; D023281:Genomics; D006801:Humans; D008297:Male; D046228:Microarray Analysis / Q000379:methods; D009362:Neoplasm Metastasis / Q000175:diagnosis*; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis*; D009693:Nucleic Acid Hybridization / Q000379:methods; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis* / Q000473:pathology / Q000628:therapy; D012307:Risk Factors
D014408:Biomarkers, Tumor